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Abstract
The evaluation of the immunosuppression state in 
liver transplanted patients is crucial for a correct post-
transplant management and a major step towards the 
personalisation of the immunosuppressive therapy. 
However, current immunological monitoring after 
liver transplantation relies mainly on clinical judgment 
and on immunosuppressive drug levels, without a 
proper assessment of the real suppression of the 
immunological system. Various markers have been 
studied in an attempt to identify a specific indicator 
of graft rejection and graft acceptance after liver 
transplantation. Considering acute rejection, the 
most studied markers are pro-inflammatory and 
immunoregulatory cytokines and other proteins re-
lated to inflammation. However there is considerable 
overlap with other conditions, and only few of them 
have been validated. Standard liver tests cannot be 
used as markers of graft rejection due to their low 
sensitivity and specificity and the weak correlation 
with the severity of histopathological findings. Several 
studies have been performed to identify biomarkers of 
tolerance in liver transplanted patients. Most of them 
are based on the analysis of peripheral blood samples 
and on the use of transcriptional profiling techniques. 
Amongst these, NK cell-related molecules seem to be 
the most valid marker of graft acceptance, whereas the 
role CD4+CD25+Foxp3+ T cells has still to be properly 
defined.
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Core tip: This review explores the available data in 
the literature concerning potential markers of acute 
cellular rejection and graft acceptance after liver 
transplantation, as well as their impact on decision-
making for clinicians.
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INTRODUCTION
During the past 25 years liver transplantation has 
become the standard therapy for acute and chronic 
liver failure. Nowadays, with a 5-year patient survival 
rate of 73%[1], long-term outcome of patients is 
becoming the main concern for clinicians, who have 
to deal with the side effects of immunosuppressant 
drugs in the long-term. 
Current immunological monitoring after liver tr-
ansplantation relies mainly on clinical judgment and 
on measurement of immunosuppressive drug levels, 
without a proper assessment of the real suppression 
of the immunological system. Therefore, the eva-
luation of the immunosuppression state in liver 
transplanted patients is crucial for a correct post-
transplant management and constitutes a major step 
towards the personalisation of immunosuppressive 
therapy.
The ideal diagnostic biomarker should be highly 
sensitive and specific, non-invasive, and rapidly 
available[2]. Despite the elevated interest in the 
evaluation of potential biomarkers of acute cellular 
rejection (ACR) and graft acceptance, and in the 
development of specific immune monitoring assays, 
only few of them are used routinely in clinical 
practice. 
The aim of this review was to explore the avai-
lable data in the literature concerning potential 
markers of ACR or graft acceptance after liver 
transplantation, as well as their impact on decision-
making for clinicians.
MARKERS OF ACUTE CELLULAR 
REJECTION
Various markers have been studied in an attempt 
to identify a specific indicator of graft rejection after 
liver transplantation. However, the use of these 
markers has been hampered by the fact that there 
is considerable overlap with other conditions, and 
currently only a few of them have been validated[3].
Liver enzymes
The suspicion of ACR is usually driven by the rise of 
liver enzymes after transplantation. However, several 
reports have clearly shown that elevated standard 
liver tests have a low sensitivity and specificity for 
ACR and show a weak correlation with the severity 
of histopathological findings[4,5]. Moreover, liver 
enzymes do not allow for ACR to be differentiated 
from others complications. A study based on 
70 post-transplant liver biopsies demonstrated 
that there is no single chemical parameter nor a 
combination of parameters that can statistically or 
clinically distinguish patients with ACR from those 
with other causes of graft dysfunction[6]. More 
recently, Rodriguez-Peralvarez et al[7] showed that 
patients with moderate/severe ACR are characterized 
by higher bilirubin levels and cholestasis parameters, 
with lower aspartate aminotransferase (AST), AST/
alanine aminotransferase (ALT) ratio than those with 
mild or no ACR. However, the combination of these 
serum parameters in the logistic regression analysis 
had only a sensitivity of 73% and a specificity of 
52.9%. ALT value was not related to the presence 
or grading of ACR, and although ALP values were 
related to ACR, this enzyme cannot be used as a 
marker of ACR nor its severity, due to the myriad of 
disorders in which it is elevated.
Cytokines
After liver transplantation, the characteristics of the 
inflammatory environment in which T cell recognition 
of the alloantigen takes place determines the lineage 
commitment of these cells. Thus, depending on the 
cytokines that are present when antigen activation 
occurs, naïve CD4+ helper T cells may acquire 
cytopathic and/or immunoregulatory phenotypes[8,9].
Based on this immunological background, the 
first potential biomarkers studied to predict ACR 
were cytokines. Products of activated T lymphocytes, 
such as IL-2 or soluble components of its receptor 
(sIL-2R), have been particularly well studied. 
Boleslawski et al[10] evaluated the intracellular IL-2 
quantification in CD3+CD8+ cells in 21 liver transplant 
recipients for 6 mo after liver transplantation, 
showing that intracellular IL-2 expression in CD8+ 
T cells before transplantation was closely related to 
the development of ACR. These results were later 
confirmed by Akoglu et al[11], who demonstrated that 
patients experiencing ACR showed a significantly 
higher intracellular percentage of IL-2+ in CD8+ T 
cells compared to stable liver transplant recipients. 
They also showed a good correlation between the 
percentage of CD8+IL-2+ cells and Banff score 
(Spearman’s rho = 0.81; p = 0.027) (Table 1). 
When the expression of IL-2 and IL-2 receptor 
was evaluated in liver grafts of patients with and 
without ACR, IL-2 and IL-2 mRNA were absent, 
with minimal expression of IL-2 receptor in patients 
experiencing ACR, whereas IL-4 and IL-4 mRNA 
were highly expressed during ACR, being absent in 
stable liver transplant recipients[12] (Table 1).
In a recent study, Millán et al[13] evaluated the 
intracellular expression and soluble production of 
IFN-γ and IL-2 in 47 liver transplanted patients. 
A pre-transplant cut-off value of 55.8% for the 
percentage of CD8+IFN-γ+ identified patients at 
high risk of ACR (sensitivity = 75% and specificity 
= 82%). In the first week after transplantation, 
patients with a percentage of inhibition for soluble 
IFN-γ, a percentage of CD8+IFN-γ+ and a percentage 
of CD8+IL2+ lower than 40%, developed ACR.
Regarding TNF-α, it has been shown that pre-
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transplant “in vitro” production of this molecule 
was significantly increased in patients with post-
transplant ACR (n = 9) compared with those who 
did not develop ACR (n = 12)[14]. When plasma 
levels of TNF-α were measured in 50 adult patients 
following liver transplantation, its concentration was 
significantly higher in patients experiencing ACR 
than in those with a stable clinical course (941 ± 83 
pg/mL vs 240 ± 6 pg/mL, p = 0.0001)[15] (Table 1). 
An important role of IL-18 in liver allograft 
rejection has been postulated in a recent study using 
a rat model of liver transplantation, which showed 
that specific suppression of IL-18 was associated 
with significantly decreased serum alanine amino-
transferase levels and less histologic hepatic injury 
early after transplantation[16] (Table 1). 
In another study, serum levels of IL-6 were 
evaluated in 20 liver transplanted patients with no 
infections, and it was demonstrated that levels of 
this cytokine were significantly higher 0-4 d before 
histological diagnosis of ACR compared to those 
of patients without ACR (131 ± 78 pg/mL vs 40 
± 21 pg/mL, p < 0.01). IL-6 elevation due to ACR 
appeared to be distinguishable from increases 
caused by infection, being serum IL-6 levels un-
relentingly elevated during bacterial infection (> 
1000 pg/mL). However, there was no correlation 
between IL-6 elevation of and histological grade of 
ACR[17] (Table 1). 
Plasma levels and “in situ” expression of IL-15 
are enhanced during ACR compared with patients 
without ACR (5.2 ± 1.3 pg/mL vs 0.6 ± 0.4 pg/mL, 
p = 0.02), with this expression being particularly 
evident when patients with steroid-resistant ACR 
were considered (6.9 ± 1.1 pg/mL)[18] (Table 1).
The role of IL-9, IL-23 and IL-17 in liver 
transplantation remains to be clarified. As far as IL-9 
is concerned, when serum levels were determined 
in 50 liver transplanted patients (15 patients with 
ACR episodes, and 35 patients without ACR) on day 
1 and 7 after liver transplantation and on the day 
of liver biopsy, no difference was found between 
patients with and without ACR[19]. Similarly, the 
serum concentrations of IL-23 and IL-17 were not 
different early in the post-transplantation period. 
However, a significant increase in serum IL-23 
levels in the ACR group was seen at the time of 
liver biopsy[19,20]. These data were confirmed by a 
latter prospective study[21] showing that the levels 
of circulating CD4+IL-17+ T cells were higher in 
patients with ACR than those with no ACR (2.56% 
± 0.43% vs 1.79% ± 0.44%, p < 0.001). Moreover, 
the frequency of CD4+IL-17+ cells in peripheral blood 
was correlated with the histological severity of ACR (r 
= 0.79, p = 0.0002) (Table 1). 
In conclusion, pro-inflammatory and immuno-
regulatory cytokines have been the most studied 
markers to predict ACR. Despite most of them 
showed an increased expression during ACR, many 
of these cytokines cannot differentiate between ACR 
and infections, making their utility limited in clinical 
practice.
Other markers related to inflammation
One of the first studies evaluating the expression of 
CD28 after liver transplantation demonstrated that 
patients experiencing ACR showed a clear increase 
with respect to patients without ACR, and to healthy 
controls. Significant differences in the total-CD28+ 
lymphocytes between the ACR and non-ACR groups 
were reached on days 7 to 9 (p < 0.01) and 10 to 
13 (p < 0.05) after transplantation[22]. The same 
group, in a subsequent study, showed that ACR and 
virus re-infection could be distinguished from each 
other because CD28 was up-regulated on CD4+ 
lymphocytes only in recipients with ACR, irrespective 
of their HBV/HCV infection status[23] (Table 1).
The expression of CD28 and CD38 was also 
analysed on CD3+, CD4+ and CD8+ cells in 52 liver 
transplanted patients in another study. The mean 
frequencies of CD28 and CD38-expressing T cells 
were significantly higher in patients with ACR (p 
= 0.01 and p = 0.001, respectively). Moreover, 
at multivariate analysis, only CD28 and CD38 
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Table 1  Marker of acute cellular rejection after liver trans­
plantation
Biomarker Sample size Ref.
Citokines  
   IL-2   66 Akoglu et al[11]
  21 Boleslawski et al[10]
   IL-4   20 Conti et al[12]
   IL-6 169 Kita et al[17]
   IL-15   35 Conti et al[18]
   IL-18 Rat model Fábrega et al[19]
   IL-23   50 Fábrega et al[20]
   IFN-γ   47 Millán et al[13]
   TNF-α   50 Imagawa et al[15]
Other markers related to 
inflammation
   CD28   55 Minguela et al[22]
237 Minguela et al[23]
  52 Boleslawski et al[24]
   CD38   52 Boleslawski et al[24]
   CD25   55 He et al[25]
   ICAM-1 NA Adams et al[26]
  12 Romero et al[27]
Bile markers
   Bikle acid concentrations   41 Janssen et al[30]
   IL-6   51 Umeshita et al[31]
   IL-8   45 Warlé et al[32]
   Alanine Aminopeptidase N     9 Kim et al[33]
Ascites markers
   IL-2 receptor   30 Ganschow et al[34]
   IL-6   30 Ganschow et al[34]
   IL-1 receptor antagonist   30 Ganschow et al[34]
IL: Interleukin; IFN: Interferon; TNF: Tumor necrosis factor; ICAM-1: 
Intercellular adhesion molecule 1.
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transplantation, seems to be a reliable marker of 
ACR, being able to differentiate between ACR and 
infection. Promising results have been found when 
eosinophil count was evaluated, especially because 
it is strongly associated with moderate-severe ACR, 
which often require steroid treatment.
Bile and ascites markers
Contrasting data are available on the role of bile and 
ascites markers as potential tools for predicting 
which patients will develop ACR after liver trans-
plantation. 
In a study on 41 patients who underwent liver 
transplantation, the investigators performed serum 
bile acid concentration measurements and correlated 
these with findings at liver biopsy. In patients with 
ACR, bile acid concentrations were statistically 
significantly increased 3 d prior to liver biopsy (from 
a mean of 37 ± 31 µmol/L to 118 ± 46 µmol/L; p = 
0.001). Moreover, successful antirejection treatment 
correlated with a significant decrease of serum bile 
acid as early as 1 d after initiation of therapy (p = 
0.008)[30] (Table 1). 
Patients with ACR showed a significant increase of 
bile IL-6 compared with patients who had uneventful 
postoperative courses (1090 ± 990 pg/mL vs 18 
± 3 pg/mL, p < 0.05) in a study performed on 51 
liver transplant recipients[31]. In a prospective study 
on 45 patients who underwent liver transplantation, 
biliary IL-8 levels were also demonstrated to be 
significantly increased at the onset of ACR (11.62 
± 4.25 pg/mL, p < 0.001) compared with patients 
with an uneventful course and those with infectious 
complications[32] (Table 1). 
Lastly, in a more recent study, alanine amino-
peptidase N (APN/CD13) enzyme activity in bile 
samples collected within 3 d before post-transplant 
liver biopsy was significantly higher in patients with 
ACR (584 ± 434 U/g protein) than in those free of 
ACR (301 ± 271 U/g protein) (p = 0.004)[33] (Table 1).
In another study, the value of cytokine quan-
tification in drained ascites was evaluated in 30 
children in the first 2 wk after liver transplantation. 
There were no significant elevations of IL-2 receptor 
and IL-6 in serum and ascites between patients 
with and without ACR. However, the concentration 
in ascites of the IL-1 receptor antagonist increased 
48 h before ACR (p = 0.01 vs no ACR). The IL-1 
receptor antagonist concentration in ascites was up 
to 11-fold higher than in serum during ACR (15.43 
vs 1.38 ng/mL)[34] (Table 1). 
In conclusion, despite encouraging results, bile 
and ascites markers have a controversial use in 
diagnosing ACR. The main limit of these diagnostic 
approaches is that they often requires invasive 
procedures such as the position of a T tube (which 
is no longer used in most of the liver transplant 
centres) or performing a paracentisis. Therefore 
frequencies at day 14 were independently associated 
with ACR (HR = 1.27, p = 0.04 and HR = 1.11, p = 
0.01 respectively)[24] (Table 1).
CD25 expression may also constitute a bio-
logical marker of immune activation in transplant 
recipients. Circulating CD4+CD25highFoxP3+ T cells 
were significantly lower in patients with ACR 
compared with patients not experiencing ACR 
(2.23% ± 0.54% vs 2.99% ± 0.86%, p = 0.01) in 
a prospective analysis of 55 patients who underwent 
liver transplantation. Longitudinal analysis revealed 
circulating CD4+CD25highFoxP3+ T cells of patients in 
the rejection group to be significantly lower during 
ACR than during quiescence (2.23% ± 0.54% vs 
3.68% ± 0.70%, p = 0.0001). Furthermore, the 
frequency of circulating CD4+CD25highFoxP3+ T cells 
negatively correlated with Rejection Activity Index (r 
= 0.80, p = 0.01)[25] (Table 1).
During graft rejection, adhesion molecules play 
a crucial role in infiltration, activation, and binding 
of effector cells to target tissues. The expression 
of intercellular adhesion molecule 1 (ICAM-1), for 
instance, has been studied on liver tissue after 
transplantation. It has been shown that ICAM-1 
expression on bile ducts, endothelium, and perivenular 
hepatocytes (structures affected by the rejection 
process) is greater in patients with ACR than in 
patients with no ACR. Moreover, it was demonstrated 
that in patients with a resolving episode of rejection 
ICAM-1 expression was greatly reduced after high-
dose corticosteroid treatment[26]. The effect of steroid 
therapy on ICAM-1 expression in liver biopsies of 
patients with post-transplant ACR was confirmed in the 
study by Romero et al[27]. After steroid treatment, the 
intensity of ICAM-1 expression decreased significantly 
in sinusoids (1.5 ± 0.67 vs 2.41 ± 0.66, p < 0.05) and 
in perivenular hepatocytes (0.25 ± 0.86 vs 0.83 ± 0.57, 
p < 0.05) compared to the pre-treatment liver biopsy 
samples (Table 1). 
Lastly, graft eosinophilia has been identified 
as an independently associated feature of ACR in 
liver transplantation[28]. In one study, the absence 
of peripheral eosinophilia predicted the absence of 
moderate/severe ACR, however it could not be used 
to predict or to assess the response to corticosteroids 
for the treatment of acute rejection[29]. In a more 
recent study, based on 690 consecutive first liver 
transplant patients and using protocol liver biopsies, 
peripheral eosinophil count was strongly associated 
with moderate-severe ACR (OR = 2.15; p = 0.007), 
although the area under ROC curve (AUROC) was 
0.58. These investigators also found that the delta 
in eosinophil count between the biopsies performed 
before and after ACR treatment was the only 
independent predictor of histological improvement 
(OR = 3.12; p = 0.001)[7] (Table 1). 
In conclusion, the expression of CD28 and 
CD38 on T cells at specific interval time form liver 
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this aspect is of great relevance in clinical practice 
because, liver biopsy, which is the gold standard for 
ACR diagnosis, is an invasive procedures and the 
clinical attention is posed mainly to non-invasive 
markers. 
Future markers
To date, the Cylex ImmuKnow assay, which quantifies 
the amount of adenosine triphosphate produced by 
CD4+ T cells after in vitro stimulation by a non-donor-
specific mitogen (phytohemagglutinin-L), is the only 
commercially available test to evaluate the immune 
status in transplanted patients.
A recent systematic literature review evaluated 
the use of ImmuKnow in liver transplant recipients. 
The study identified five studies analysing ImmuKnow 
performance for infection and 5 studies analysing 
ImmuKnow performance for ACR. Considering 
the ability to predict ACR, the pooled sensitivity, 
specificity, positive likelihood ratio, diagnostic odds 
ratio, and AUROC curve for this analysis were 
65.6% (95%CI: 55.0%-75.1%), 80.4% (95%CI: 
76.4%-83.9%), 3.4 (95%CI: 2.4-4.7), 8.8 (95%CI: 
3.1-24.8), and 0.835 ± 0.060 respectively, while 
the respective values in the setting of infection were 
83.8% (95%CI: 78.5%-88.3%), 75.3% (95%CI: 
70.9%-79.4%), 3.3 (95%CI: 2.8-4.0), 14.6 (95%CI: 
9.6-22.3), and 0.824 ± 0.034, respectively. Notably, 
heterogeneity was low for infection studies and high 
for ACR studies[35]. Based on these data, it appears 
that this assay could be more useful in order to 
assess over-immunosuppression rather than under-
immunosuppression[36]. 
Due to the high number of proteins involved in 
the ACR process, proteomic analysis could have a 
crucial role in identifying a potential biomarker of 
ACR. However, despite several studies have been 
performed, the results are not conclusive and these 
techniques have to progress from the research 
bench to the clinical routine[37].
In conclusion, future markers of ACR such as 
ImmuKnow and proteomic analysis, have been 
evaluated, but well designed, prospective studied 
are needed in order to better understand their 
clinical applicability.
MARKERS OF GRAFT ACCEPTANCE
To date, liver biopsy is the gold standard to assess 
the graft status after liver transplantation, but it is an 
invasive procedure and is not suitable for monitoring 
the graft on a daily basis. Moreover, it does not 
provide any useful information for predicting future 
development of tolerance[38]. Therefore, biomarkers 
of graft acceptance could be crucial in order to select 
patients eligible for enrolment in immunosuppressive 
drug weaning or withdrawal protocols. Thus, several 
studies have been performed to identify biomarkers 
of tolerance in liver transplanted patients; most of 
them are based on the analysis of peripheral blood 
samples and on the use of transcriptional profiling 
techniques[39].
Non-specific genomic analysis
In the first study using microarray gene expression 
profiling, Martínez-Llordella et al[40] found that 
genes encoding for γδT-cell, for NK receptors, and 
for proteins involved in cell proliferation arrest 
were up-regulated in tolerant liver transplanted 
patients (n = 16) compared to immunosuppression-
dependent patients (n = 16) or healthy individuals 
(n = 10). A second study by the same group, 
using a larger cohort of patients, confirmed these 
results. Again, NK cell and γδTCR+ T cell transcripts 
were predominantly expressed in tolerant liver 
transplanted patients[41].
In a more recent study, transcriptional profiles 
from 300 samples were examined by microarrays 
and RT-PCR measurements of blood specimens 
from paediatric and adult liver transplant recipients 
and of normal tissues. Tolerance-specific genes 
were validated in independent samples across two 
different transplant programs and validated by RT-
PCR. A minimal set of 13 unique genes, highly 
expressed in NK cells (p = 0.03), were significantly 
expressed in both paediatric and adult liver 
transplanted tolerant patients, and the performance 
of this gene set analysis, tested in independent 
samples, yielded a 100% sensitivity and 83% 
specificity[42].
Lastly, Bohne et al[43] recently reported the re-
sults of a multicentre prospective study evaluating 
75 liver transplant recipients from whom cryopre-
served liver tissue samples had been obtained 
before the initiation of drug minimization and were 
available for transcriptional analyses. Amongst 
these, 33 recipients successfully discontinued all 
immunosuppressive drugs, while 42 rejected their 
allografts. Before initiation of drug withdrawal, 
operationally tolerant and non-tolerant recipients 
differed in the intragraft expression of genes 
involved in the regulation of iron homeostasis. 
Moreover, operationally tolerant patients exhibited 
higher serum levels of hepcidin and ferritin and 
increased hepatocyte iron deposition compared to 
non-tolerant ones.
Peripheral blood immunophenotyping
An increase Vδ1/Vδ2 γδT-cells ratio has been found 
in operationally tolerant liver transplanted patients 
(n = 12, ratio = 1.5) when compared with liver 
transplanted patients on immunosuppression (n = 
19, ratio = 0.8; p < 0.01) and with age-matched 
healthy controls (n = 24, ratio = 0.3; p < 0.05)[44]. 
The increase in the number of circulating Vδ1+ T 
cells in tolerant patients has also been confirmed 
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in a later study by Martínez-Llordella et al[40] who 
demonstrated that Vδ1+ subtype is the predominant 
γδT-cell subpopulation in tolerant recipients. 
Based on this, altered distribution of the Vδ1 
and Vδ2 γδT cells in operationally tolerant liver 
transplant recipients, γδT cells subset quantification 
was proposed as a biomarker of immunologic risk 
in liver transplantation. However, a recent study 
showed that alterations in the γδT cell compartment 
are not restricted to tolerant liver recipients, and 
that most immunosuppressed liver recipients display 
an enlarged peripheral blood γδT cell pool mainly 
resulting from an expansion of Vδ1 T cells exhibiting 
an oligoclonal repertoire and different phenotypic 
and cytokine production traits than Vδ2 T cells. 
The authors proposed that persistent viral infection 
might be the cause of these alterations[45]. 
Several studies have shown that the numbers 
of circulating CD4+CD25+ T-cells is increased in 
operationally tolerant patients after liver trans-
plantation[40,44,46,47]. When peripheral blood mono-
nuclear cell populations were analysed in 12 liver 
transplant recipients with stable graft function for 
more than 2 years, the percentage of CD4+CD25high+ 
cells was significantly higher in tolerant patients 
(n = 12, 2.3% ± 0.6%), compared with patients 
who were still on immunosuppression (n = 19, 
0.9% ± 0.7%; p < 0.01), and with age-matched 
volunteers (n = 24, 1.8% ± 0.6%; p < 0.05)[44]. 
This data were confirmed by Pons et al[46] who 
found an increased frequency of CD4+CD25high+ 
cells when immunosuppressive therapy was 
withdrawn in tolerant patients (n = 5). The most 
interesting data of this study was that relative 
mRNA FoxP3 expression increased 3.5-fold before 
the complete withdrawal of immunosuppression 
in tolerant patients, and this increase continued 
when the immunosuppressive therapy was stopped. 
Conversely, patients who suffered ACR (n = 7) did 
not exhibit an increase in CD4+CD25high+ cells or 
FoxP3 expression.
When the expression of Foxp3 mRNA and the 
presence of CD4, CD8, and Foxp3 cells were 
quantified in liver biopsies from tolerant living-
donor liver transplanted patients, it was found that 
Foxp3 mRNA expression was higher in tolerant 
patients (n = 28), compared with patients on 
immunosuppression (n = 29; p = 0.07), but was 
equivalent to patients who experienced chronic 
rejection (n = 7; p < 0.01). The number of Foxp3 
cells was significantly increased in tolerant patients, 
compared with patients on immunosuppression (p < 
0.05), although the number of CD4 or CD8 cells did 
not differ between the two groups[48].
CONCLUSION
The evaluation of the real suppression of the im-
mune system after liver transplantation would 
allow transplant clinicians to modulate the immuno-
suppressive therapy according to patient needs, 
identifying, not only patients at risk of acute re-
jection, and infection, but also understanding if the 
immunological background would allow a progressive 
reduction of the immunosuppressive therapy, favou-
ring graft acceptance.
Despite these considerations, the current im-
munological monitoring after liver transplantation relies 
mainly on clinical judgment and on immunosuppressive 
drug levels, without a proper assessment of the real 
suppression of the immunological system. 
Therefore, it becomes crucial to identify potential 
biomarkers of immune activity, which can be used to 
tailor immunosuppression after liver transplantation.
In this manuscript, we reviewed available data on 
studies assessing the role of different biomarkers of 
ACR and graft acceptance after liver transplantation.
Considering biomarkers for ACR, pro-inflammatory 
and immunoregulatory cytokines are the most stu-
died ones, showing an increased expression during 
ACR. However many of these cytokines cannot 
differentiate between ACR and infections, making 
their utility limited in clinical practice. The expression 
of other proteins related to inflammation, not only in 
the blood, but also in the bile and in the ascites has 
been evaluated, but the results are controversial. 
Moreover, the use of ascites markers is an invasive 
method and it needs the presence of ascites after 
liver transplantation, therefore it is not applicable on 
a daily basis.
When we evaluated available markers of graft 
acceptance after liver transplantation, we found that 
data are more encouraging compared to biomarkers 
of ACR. Patients undergoing immunosuppression 
withdrawal seem to present specific characteristics 
compared to non-tolerant patients. One of the most 
reliable blood marker, which could help clinicians 
to differentiate between tolerant and non-tolerant 
patients, are NK cells and their related transcripts. It 
has been clearly demonstrated that they are already 
present in the blood of tolerant liver transplanted 
patients before the withdrawal of immunosuppressive 
therapy. The role CD4+CD25+Foxp3+ T cells, which 
seem to have a immunoregulatory effect, is less 
clear due to the use of immunosuppressive drugs, 
which could alter their expression. Independently 
from the markers identified, there is a substan-
tial difference between the expression of specific 
markers in the blood and their expression in the 
transplanted liver. This difference makes blood-
related biomarkers less accurate in order to pre-
dict graft acceptance and forces clinician still to 
use liver biopsy to monitor patients undergoing 
immunosuppression withdrawal.
Lastly, it is becoming evident that a single 
biomarker cannot be able to reflect all the altera-
tions of the immune system associated with organ 
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transplantation. Therefore a panel of different bio-
markers will be needed to properly evaluate the 
immunological suppression and to modify immuno-
suppressive treatment according to patient needs. 
Once a panel of markers is identified, it should 
undergo validation in large multicentre studies in 
order to prove its real clinical utility.
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